retatrutide clinical trial phase for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational trials - Giblin - 2026 - Diabetes, Obesity and Metabolism Retatrutide for the treatment of
Description
95% CI 0.89, 0.96) and all-cause mortality rate (HR 0.70
95% CI: 0.8, 0.9
Although long-term safety and efficacy require further evaluation, current evidence positions GLP-1 RAs as promising therapeutic agents in translational geroscience, with the potential to mitigate age-related physiological decline and promote a longer, healthier lifespan.
The experimental weight loss drug retatrutide could also help to improve liver health, a new study suggests
COA y reporte MS descargables
And its definitely not what you expect.I started my journey on a GLP-1 in October 2024
